Connections between vascular calcification and progression of chronic kidney disease: Therapeutic alternatives

Kidney International

Volumn 68, Issue SUPPL. 99, 2005, Pages

  Hruska, Keith A ^a   Mathew, Suresh ^a   Davies, Matthew R ^a   Lund, Richard J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adynamic bone disorder; BMP 7; Chronic kidney disease; Hyperphosphatemia; Metabolic syndrome; Renal osteodystrophy; Type 2 diabetes; Vascular calcification

Indexed keywords

CALCIUM CARBONATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; OSTEOGENIC PROTEIN 1; PHOSPHATE; BONE MORPHOGENETIC PROTEIN; CALCIUM; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; BONE DISEASE; BONE MINERALIZATION; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HYPERPHOSPHATEMIA; KIDNEY INJURY; LIPID DIET; MALE; METABOLIC SYNDROME X; MORTALITY; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; SUPPLEMENTATION; VASCULAR SMOOTH MUSCLE; ANIMAL; ARTICLE; BLOOD; BONE DEVELOPMENT; C57BL MOUSE; CALCINOSIS; CHEMISTRY; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; DRUG EFFECT; FAT INTAKE; HYPERPARATHYROIDISM; KIDNEY DISEASE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RENAL OSTEODYSTROPHY; THORACIC AORTA;

ANIMALS; AORTA, THORACIC; BONE DISEASES; BONE MORPHOGENETIC PROTEINS; CALCINOSIS; CALCIUM; CALCIUM CARBONATE; CHRONIC DISEASE; DIETARY FATS; DISEASE PROGRESSION; FEMALE; HYPERPARATHYROIDISM; KIDNEY DISEASES; MALE; MICE; MICE, INBRED C57BL; OSTEOBLASTS; OSTEOGENESIS; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC; RENAL OSTEODYSTROPHY; TRANSFORMING GROWTH FACTOR BETA;

EID: 33748320768     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.09926.x     Document Type: Conference Paper

References (95)

1. ANAVEKAR NS, MCMURRAY JJV, VELAZQUEZ EJ, et al: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351:1285-1295, 2004
2. CHEN J, MUNTNER P, HAMM LL, et al: The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 140:167-174, 2004
3. AITMAN TJ, GOTODA T, EVANS AL, et al: Quantitative trait loci for cellular defects in glucose and fatty acid metabolism in hypertensive rats. Nat Genet 16:197-201, 1997
4. KNOWLES JW, MAEDA N: Genetic modifiers of atherosclerosis in mice. Arterioscler Thromb Vasc Biol 20:2336-2345, 2000
5. SCHAEFFNER ES, KURTH T, CURHAN GC, et al: Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Neph 14:2084-2091, 2003
6. REAVEN GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
7. REILLY MP, RADER DJ: The metabolic syndrome: More than the sum of its parts? Circulation 108:1546-1551, 2003
8. MODAN M, HALKIN H, ALMOG S, et al: Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin Invest 75:809-817, 1985
9. MARTIN BC, WARRAM JH, KROLEWSKI AS, et al: Role of glucose and insulin resistance in development of type 2 diabetes mellitus: Results of a 25-year follow-up study. Lancet 340:925-929, 1992
10. HAFFNER SM, VALDEZ RA, HAZUDA HP, et al: Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 41:715-722, 1992
11. ISOMAA B, ALMGREN P, TUOMI T, et al: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683-689, 2001
12. LAKKA HM, LAAKSONEN DE, LAKKA TA, et al: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709-2716, 2002
13. FOLEY RN, PARFREY PS, SARNAK MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:S112-S119, 1998
14. MUNTNER P, HE J, HAMM L, et al: Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 13:745-753, 2002
15. GERSTEIN HC, MANN JFE, YI Q, et al: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421-426, 2001
16. CULLETON BF, LARSON MG, WILSON PWF, et al: Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 56:2214-2219, 1999
17. UNITED STATES RENAL DATA SYSTEM: Annual Data Report 2002: Atlas of End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2004
18. DAVIES MR, LUND RJ, HRUSKA KA: BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Neph 14:1559-1567, 2003
19. VUKICEVIC S, BASIC V, ROGIC D, et al: Osteogenic protein-1 (Bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. J Clin Invest 102:202-214, 1998
20. WANG S, HIRSCHBERG R: BMP7 antagonizes TGF-beta-dependent fibrogenesis in mesangial cells. Am J Phys (Renal) 284:F1006-F1013, 2003
21. HRUSKA K, GUO G, WOZNIAK M, et al: Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am J Phys (Renal) 279:F130-F143, 2000
22. ZEISBERG M, HANAI J, SUGIMOTO H, et al: BMP-7 counteracts TGFβ1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nature Med 9:964-968, 2003
23. HRUSKA KA, GUO G, WOZNIAK M, et al: Osteogenic protein-1 (OP-1) prevents renal fibrogenesis associated with ureteral obstruction. Am J Phys (Renal) 279:F130-F143, 2000
24. WANG S, CHEN Q, SIMON TC, et al: Bone morphogenetic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int 63:2037-2049, 2003
25. LUND RJ, DAVIES MR, BROWN AJ, HRUSKA KA: Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model. J Am Soc Neph 15:359-369, 2004
26. GONZALEZ EA, LUND RJ, MARTIN KJ, et al: Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7. Kidney Int 61:1322-1331, 2002
27. BOSTROM K, WATSON KE, STANFORD WP, DEMER LL: Atherosclerotic calcification: Relation to developmental osteogenesis. Am J Cardiol 75:88B-91B, 1995
28. DEMER L: Lipid hypothesis of cardiovascular calcification. Circulation 95:297-298, 1997
29. PRICE PA, FAUS SA, WILLIAMSON MK: Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol 20:317-327, 2000
30. GIACHELLI CM, SCHWARTZ SM, LIAW L: Molecular and cellular biology of osteopontin: Potential role in cardiovascular disease. Trends Cardiovasc Med 5:88-95, 1995
31. JONO S, PEINADO C, GIACHELLI CM: Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem 275:20197-20203, 2000
32. HEINO J, MASSAGUE J: Transforming growth factor-beta switches the pattern of integrins expressed in MG-63 human osteosarcoma cells and causes a selective loss of cell adhesion to laminin. J Biol Chem 264:21806-21811, 1989
33. STEITZ SA, SPEER MY, CURINGA G, et al: Smooth muscle cell phenotypic transition associated with calcification. Circ Res 89:1147-1154, 2001
34. JONO S, MCKEE MD, MURRY CE, et al: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87:e10-e17, 2000
35. SAAB G, HRUSKA KA: Role of bone morphogenetic proteins in vascular calcification. Circ Res 97: 105-114, 2005
36. GAGNON RF, GALLIMORE B: Characterization of a mouse model of chronic uremia. Urol Res 16:119-126, 1988
37. PRICE PA, FAUS SA, WILLIAMSON MK: Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 18:1400-1407, 1998
38. PARFITT AM, DREZNER MK, GLORIEUX FH, et al: Bone histomorphometry: Standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595-610, 1987
39. CHAUDHARY LR, HOFMEISTER AM, HRUSKA KA: Differential growth factor control of bone formation through osteoprogenitor differentiation. Bone 34:402-411, 2004
40. PHINNEY DG, KOPEN G, ISAACSON RL, PROCKOP DJ: Plastic adherent stromal cells from the bone marrow of commonly used strains of inbred mice: Variations in yield, growth, and differentiation. J Cell Biochem 77:570-585, 1999
41. LITTLE RD, CARULLI JP, DELMASTRO RG, et al: A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70:11-19, 2002
42. 1. J Biochem 124:1072-1076, 1998
43. HOLTZMAN DM, PITAS RE, KILBRIDGE J, et al: Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. Proc Natl Acad Sci U S A 92:9480-9484, 1995
44. FAGAN AM, BU G, SUN Y, et al: Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein. J Biol Chem 271:30121-30125, 1996
45. LEON M, LARRODERA L, LLEODO G, HAWKINS F: Study of bone loss in diabetes mellitus type 1. Diabetes Res Clin Pract 6:237-242, 1989
46. VERHAEGHE J, BOUILLON R: Effects of diabetes and insulin on bone physiology, in Principles of Bone Biology, edited by Bilezikian JP, Raisz LG, Rodan GA, San Diego, Academic Press, 2002, pp 741-755
47. LEVIN ME, BOISSEAU VC, AVIOLI LV: Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes. N Engl J Med 294:241-245, 1976
48. KRAKAUER JC, MCKENNA MJ, BUDERER NF, et al: Bone loss and bone turnover in diabetes. Diabetes 44:775-782, 1995
49. HRUSKA KA, TEITELBAUM S: New features of renal osteodystrophy. N Engl J Med 333:166-174, 1995
50. MUCSI I, HERCZ G: Relative hypoparathyroidism and adynamic bone disease. Am J Med Sci 317:405-409, 1999
51. HERCZ G, PEI Y, GREENWOOD C, et al: A plastic osteodystrophy without aluminum: The role of "suppressed" parathyroid function. Kidney Int 44:860-866, 1993
52. CUPPARI L, CARVALHO AB, LOBAO RRS, et al: Parathyroid hormone changes during phosphorus load in patients with chronic renal insufficiency with low serum parathyroid hormone or adynamic bone disease. Clin Nephrol 56:35-43, 2001
53. ANDRESS DL, HERCZ G, KOPP JB, et al: Bone histomorphometry of renal osteodystrophy in diabetic patients. J Bone Min Res 2:525-531, 1987
54. PEI Y, HERCZ G, GREENWOOD C, et al: Renal osteodystrophy in diabetic patients. Kidney Int 44:159-164, 1993
55. JARA A, BOVER J, FELSENFELD AJ: Development of secondary hyperparathyroidism and bone disease in diabetic rats with renal failure. Kidney Int 47:1746-1751, 1995
56. ATSUMI K, KUSHIDA K, YAMAZAKI K, et al: Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 33:287-293, 1999
57. SANCHEZ CP, KUIZON BD, ABDELLA PA, et al: Impaired growth, delayed ossification, and reduced osteoclastic activity in the growth plate of calcium-supplemented rats with renal failure. Endocrinology 141:1536-1544, 2000
58. KUIZON BD, SALUSKY IB: Growth retardation in children with chronic renal failure. J Bone Miner Res 14:1680-1690, 1999
59. LUND RJ, DAVIES MR, HRUSKA KA: Bone morphogenetic protein-7: An anti-fibrotic morphogenetic protein with therapeutic importance in renal disease. Curr Opin Nephrol Hypertens 11:31-36, 2002
60. GUERIN AP, LONDON GM, MARCHAIS SJ, METIVIER F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15:1014-1021, 2000
61. SLATOPOLSKY E, FINCH J, CLAY P, et al: A novel mechanism for skeletal resistance in uremia. Kidney Int 58:753-761, 2000
62. LLACH F, MASSRY SG, SINGER FR: Skeletal resistance of endogenous parathyroid hormone in patients with early renal failure. A possible cause for secondary hyperparathyroidism. J Clin Endocrin Metab 41:339-345, 1975
63. TSUGAWA K, JONES MK, SUGIMACHI K, et al: Biological role of phosphatase PTEN in cancer and tissue injury healing. Front Biosci 7:e245-e251, 2002
64. ISOGAI Y, AKATSU T, ISHIZUYA T, et al: Parathyroid hormone regulates osteoblast differentiation positively or negatively depending on the differentiation stages. J Bone Miner Res 11:1384-1393, 1996
65. 3, parathyroid hormone and glucocorticoids. Metab Bone Disease Rel Res 5:229-234, 1984
66. BOGDANOVIC Z, HUANG Y-F, DODIG M, et al: Parathyroid hormone inhibits collagen synthesis and the activity of rat Collal transgenes mainly by a cAMP-mediated pathway in mouse calvariae. J Cell Biochem 77:149-158, 2000
67. CHAUDHARY LR, AVIOLI LV: Identification and activation of mitogen-activated protein (MAP) kinase in normal human osteoblastic and bone marrow stromal cells: Attenuation of MAP kinase activation by cAMP, parathyroid hormone and forskolin. Mol Cell Biochem 178:59-68, 1998
68. UZAWA T, HORI M, EJIRI S, OZAWA H: Comparison of the effects of intermittent and continuous administration of human parathyroid hormone (1-34) on rat bone. Bone 16:477-484, 1995
69. BURGESS TL, QIAN Y-X, KAUFMAN S, et al: The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145:527-538, 1999
70. HSU H, LACEY DL, DUNSTAN CR, et al: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 96:3540-3545, 1999
71. HRUSKA KA: Pathophysiology of renal osteodystrophy. Pediatr Nephrol 14:636-640, 2000
72. LUO G, HOFMANN C, BRONCKERS AL, et al: BMP-7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning. Genes Dev 9:2808-2820, 1995
73. JENA N, MARTIN-SEISDEDOS C, MCCUE P, CROCE CM: BMP7 null mutation in mice: Developmental defects in skeleton, kidney, and eye. Exp Cell Res 230:28-37, 1997
74. DUDLEY AT, LYONS KM, ROBERTSON EJ: A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye. Genes Dev 9:2795-2807, 1995
75. ROSEN V, WOZNEY JM: Bone morphogenetic proteins, in Principles of Bone Biology, edited by Bilezikian JP, Raisz LG, and Rodan GA, San Diego, Academic Press, 1996, pp 919-928
76. DUCY P, KARSENTY G: The family of bone morphogenetic proteins. Kidney Int 57:2207-2214, 2000
77. URIST MR: Bone formation by autoinduction. Science 150:893-899, 1965
78. WANG EA, ISRAEL DI, KELLY S, LUXENBERG DP: Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and 3T3 cells. Growth Factors 9:57-71, 1993
79. THIES RS, BAUDUY M, ASHTON BA: Recombinant human bone morphogenetic protein-2 induces osteoblastic differentiation in W-20-17 stromal cells. Endocrinology 130:1318-1324, 1992
80. AHRENS M, ANKENBAUER T, SCHRODER D: Expression of human bone morphogenetic proteins-2 or -4 in murine mesenchymal progenitor C3H10T1/2 cells induces differentiation into distinct mesenchymal cell lineages. DNA Cell Biology 12:871-880, 1993
81. YAMASHITA H, TENDIJKE P, HELDIN CH, MIYAZONO K: Bone morphogenetic protein receptors. Bone 19:569-574, 1996
82. MIYAZONO K: Signal transduction by bone morphogenetic protein receptors. Bone 25:91-93, 1999
83. MILJAVAC V, GRGUREVIC L, BATINIC D, VUKICEVIC S: Identification of bone morphogenetic proteins in urine by western blotting and ELISA. Calcif Tissue Int 70:270, 2003
84. SAMPATH TK, MALIAKAL JC, HAUSCHKA PV, et al: Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J Biol Chem 267:20352-20362, 1992
85. KITTEN AM, LEE JC, OLSON MS: Osteogenic protein-1 enhances phenotypic expression in ROS 17/2.8 cells. Amer J Physiol 269:E918-E926, 1995
86. FRANCESCHI RT, WANG D, KREBSBACH PH, RUTHERFORD RB: Gene therapy for bone formation: In vitro and in vivo osteogenic activity of an adenovirus. J Cell Biochem 781:476-486, 2000
87. LLACH F, BOVER J: Renal osteodystrophies, in The Kidney, edited by Brenner BM, Philadelphia, WB Saunders Company, 2000, pp 2103-2186
88. BLOCK GA, PORT FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 35:1226-1237, 2000
89. DAVIES MR, HRUSKA KA: Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int 60:472-479, 2001
90. LONDON GM, GUERIN AP, MARCHAIS SJ, et al: Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18:1731-1740, 2003
91. RAGGI P, BOULAY A, CHASAN-TABER S, et al: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39:695-701, 2002
92. GOODMAN WG, GOLDIN J, KUIZON BD, et al: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483, 2000
93. GANESH SK, STACK AG, LEVIN NW, et al: Association of elevated serum po(4), ca x po(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131-2138, 2001
94. DUCY P, KARSENTY G: The family of bone morphogenetic proteins. Kidney Int 57: 2207-2714, 2000
95. WANG SN, LAPAGE J, HIRSCHBERG R: Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J Am Soc Nephrol 12:2392-2399, 2001